The invention relates to oligomeric compounds (oligomers), which target beta-cateninmRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-cateninexpression is beneficial for a range of medical disorders, such as hyperproliferativediseases, including cancer. The invention provides therapeutic compositionscomprising oligomers and methods for modulating the expression of beta-cateninusing said oligomers, including methods of treatment.
